Adhikari, Hema
Counter, Christopher M.
Funding for this research was provided by:
Pancreatic Cancer Action Network (17-40-ADHI)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA123031, P01CA203657)
Article History
Received: 7 November 2017
Accepted: 19 July 2018
First Online: 7 September 2018
Competing interests
: C.M.C. is the co-recipient of a grant from GSK entitled “Developing PIP5K1A inhibitors for the treatment of oncogenic KRAS-driven cancers.” This grant neither supported this study nor had any role in the conceptualization, design, data collection, analysis, or decision to publish or prepare the manuscript. The remaining author declares no competing interests.